Elevated cortical zinc in Alzheimer disease

Neurology

Volumn 67, Issue 1, 2006, Pages 69-75

  Religa, D ^a,b   Strozyk, D ^c   Cherny, R A ^f,g   Volitakis, I ^f,g   Haroutunian, V ^d   Winblad, B ^a   Naslund, J ^a   Bush, A I ^e,f,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; COPPER; IRON; MANGANESE; METAL; ZINC; AMYLOID; HEAVY METAL;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; BRAIN CORTEX; BRAIN LEVEL; CADAVER; CHEMICAL ANALYSIS; COGNITION; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEOCORTEX; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TISSUE LEVEL; AGE; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; NEUROFIBRILLARY TANGLE; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CEREBRAL CORTEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METALS, HEAVY; NEUROFIBRILLARY TANGLES; POSTMORTEM CHANGES; SCHIZOPHRENIA; STATISTICS; ZINC;

EID: 33746800368     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000223644.08653.b5     Document Type: Article

References (81)

1. Glenner GG, Wong CW,. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
2. Bush AI. Metallobiology of Alzheimer's disease. Trends Neurol Sci 2003;26:207-214.
3. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 1994;265:1464-1467.
4. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826.
5. 2. J Biol Chem 2002;277:40302-40308.
6. Dong J, Atwood CS, Anderson VE, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003;42:2768-2773.
7. Schubert D, Chevion M. The role of iron in β amyloid toxicity. Biochem Biophys Res Commun 1995;216:702-707.
8. Huang X, Atwood CS, Hartshorn MA, et al. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999;38:7609-7616.
9. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999;274:37111-37116.
10. Rottkamp C, Raina A, Zhu X, et al. Redox-active iron mediates amyloid-β toxicity. Free Rad Biol Med 2001;30:447-450.
11. Puglielli L, Friedlich AL, Setchell KDR, et al. Cholesterol oxidase mimetic activity of Alzheimer's disease β-amyloid. J Clin Invest 2005;115:2556-2563.
12. Howell GA, Welch MG, Frederickson CJ. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 1984;308:736-738.
13. Frederickson CJ, Koh JY, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci 2005;6:449-462.
14. Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci USA 1996;93:14934-14939.
15. Friedlich AL, Lee JY, van Groen T, et al. Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci 2004;24:3453-3459.
16. Lee J-Y, Cole TB, Palmiter RD, Suh SW, Koh J-Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 2002;99:7705-7710.
17. Hartter DE, Barnea A. Evidence for release of copper in the brain: depolarization-induced release of newly taken-up 67copper. Synapse 1988;2:412-415.
18. Schlief ML, Craig AM, Gitlin JD. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 2005;25:239-246.
19. 2+ complexes in Alzheimer's disease. Aging Cell 2006;5:69-79.
20. Religa D, Laudon H, Styczynska M, Winblad B, Naslund J, Haroutunian V. Amyloid beta pathology in Alzheimer's disease and schizophrenia. Am J Psychiatry 2003;160:867-872.
21. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD); part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
22. Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998;55:1185-1191.
23. Terry RD, Katzman R. Senile dementia of the Alzheimer's type: defining a disease. In: Terry RKaRD, ed. The neurology of aging. New York: Davis, 1983:51-84.
24. Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 1985;5:2801-2808.
25. Ichinohe N, Rockland KS. Distribution of synaptic zinc in the macaque monkey amygdala. J Comp Neurol 2005;489:135-147.
26. Cairns NJ, Chadwick A, Luthert PJ, Lantos PL. Beta-amyloid protein load is relatively uniform throughout neocortex and hippocampus in elderly Alzheimer's disease patients. Neurosci Lett 1991;129:115-118.
27. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
28. McLean C, Cherny R, Fraser F, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
29. Barghorn S, Nimmrich V, Striebinger A, et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005;95:834-847.
30. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988;38:1688-1693.
31. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1996;143:137-142.
32. Danscher G, Jensen KB, Frederickson CJ, et al. Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 1997;76:53-59.
33. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998;19:339-345.
34. Thompson CM, Markesbery WR, Alaudin M, Hossain TIM, Brubaker EH. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology 1988;9:1-8.
35. Samudralwar DL, Diprete CC, Ni BF, Ehmann WD, Markesbery WR. Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 1995;130:139-145.
36. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52.
37. Deng QS, Turk GC, Brady DR, Smith QR. Evaluation of brain element composition in Alzheimer's disease using inductively-coupled plasma mass spectrometry. Neurobiol Aging 1994;15(suppl 1):S113-S110.
38. Andrasi E, Farkas E, Scheibler H, Reffy A, Bezur L. Al, Zn, Cu, Mn and Fe levels in brain in Alzheimer's disease. Arch Gerontol Geriatr 1995;21:89-97.
39. Ward NI, Mason JA. Neutron activation analysis for identifying elemental status in Alzheimer's disease. J Radioanal Nucl Chem 1987;113:515-526.
40. Landsberg JP, McDonald B, Watt F. Absence of aluminum in neuritic plaque cores in Alzheimer's disease. Nature 1992;360:65-68.
41. Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000;852:274-278.
42. Lee J-Y, Mook-Jung I, Koh J-Y. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J. Neuroscience 1999;19:1-5.
43. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with Alzheimer Aβ peptides - identification of an attomolar affinity copper binding site on Aβ1-42. J Neurochem 2000;75:1219-1233.
44. Maynard CJ, Cappai R, Volitakis I, et al. Overexpression of Alzheimer's disease β-amyloid opposes the age-dependent elevations of brain copper and iron levels. J Biol Chem 2002;277:44670-44676.
45. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-279.
46. Koh J-H, Suh SW, Gwag BJ, He YY, Hsu CY, Choi DW. The role of zinc in selective neuronal death after transient global cerebral ischemia. Science 1996;272:1013-1016.
47. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD. Disruption of the metallothionein-III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 1997;17:1271-1281.
48. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth-inhibitory factor that is deficient in the Alzheimer's disease brain is a 68-amino acid metallothionein-like protein. Neuron 1991;7:337-347.
49. 2+ inhibits alpha-ketoglutarate-stimulated mitochondrial respiration and the isolated alpha-ketoglutarate dehydrogenase complex. J Biol Chem 2000;275:13441-13447.
50. Kamimura S, Mandelkow E. Tubulin protofilaments and kinesin-dependent motility. J Cell Biol 1992;118:865-875.
51. Kim I, Kim CH, Kim JH, et al. Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp Cell Res 2004;298:229-238.
52. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002;81:1-8.
53. Flinn JM, Hunter D, Linkous DH, et al. Enhanced zinc consumption causes memory deficits and increased brain levels of zinc. Physiol Behav 2005;83:793-803.
54. Tarohda T, Yamamoto M, Amamo R. Regional distribution of manganese, iron, copper, and zinc in the rat brain during development. Anal Bioanal Chem 2004;380:240-246.
55. Maynard CJ, Cappai R, Volitakis I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002;277:44670-44676.
56. Loeffler DA, LeWitt PA, Juneau PL, et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res 1996;738:265-274.
57. Plantin LO, Lying-Tunell U, Kristensson K. Trace elements in the human central nervous system studied with neutron activation analysis. Biol Trace Elem Res 1987;13:69-75.
58. Rao K, Rao R, Shanmugavelu P, Menon R. Trace elements in Alzheimer's disease brain: a new hypothesis. Alzheimers Rep 1999;2:241-246.
59. Opazo C, Huang X, Cherny RA, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002;277:40302-40308.
60. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci. 1996;143 (1-2):137-142.
61. Plantin L-O, Lysing-Tunnell U, Kristensson K. Trace elements in the human central nervous system studied with neutron activation analysis. Biol Trace Elem Res 1987;13:69-75.
62. Rao KSJ, Rao RV, Shanmugavelu P, Menon RB. Trace elements in Alzheimer's disease brain: a new hypothesis. Alzheimers Rep 1999;2:241-246.
63. Sullivan PG, Brown MR. Mitochondrial aging and dysfunction in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:407-410.
64. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 2000;21:455-462.
65. Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 2004;25:105-110.
66. Cottrell DA, Blakely EL, Johnson MA, Ince PG, Turnbull DM. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 2001;57:260-264.
67. De Deyn PP, Hiramatsu M, Borggreve F, et al. Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis 1998;12:26-32.
68. Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J Alzheimers Dis 1999;1:139-145.
69. Schuessel K, Schafer S, Bayer TA, et al. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis 2005;18:89-99.
70. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002;59:1153-1161.
71. Squitti R, Cassetta E, Dal Forno G, et al. Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment. Arch Neurol 2004;61:738-743.
72. Bayer TA, Schafer S, Simons A, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid A{beta} production in APP23 transgenic mice. Proc Natl Acad Sci USA 2003;100:14187-14192.
73. Phinney AL, Drisaldi B, Schmidt SD, et al. In vivo reduction of amyloid-{beta} by a mutant copper transporter. Proc Natl Acad Sci USA 2003;100:14193-14198.
74. White AR, Reyes R, Mercer JF, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 1999;842:439-444.
75. Bellingham SA, Ciccotosto GD, Needham BE, et al. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem 2004;91:423-428.
76. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-9868.
77. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-1691.
78. Kaur D, Yantiri F, Kumar J, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:923-933.
79. Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102:11840-11845.
80. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
81. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004;25:1315-1321.